Correlation Between Liaoning Chengda and Contemporary Amperex

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Liaoning Chengda and Contemporary Amperex at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Liaoning Chengda and Contemporary Amperex into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Liaoning Chengda Biotechnology and Contemporary Amperex Technology, you can compare the effects of market volatilities on Liaoning Chengda and Contemporary Amperex and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Liaoning Chengda with a short position of Contemporary Amperex. Check out your portfolio center. Please also check ongoing floating volatility patterns of Liaoning Chengda and Contemporary Amperex.

Diversification Opportunities for Liaoning Chengda and Contemporary Amperex

0.96
  Correlation Coefficient

Almost no diversification

The 3 months correlation between Liaoning and Contemporary is 0.96. Overlapping area represents the amount of risk that can be diversified away by holding Liaoning Chengda Biotechnology and Contemporary Amperex Technolog in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Contemporary Amperex and Liaoning Chengda is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Liaoning Chengda Biotechnology are associated (or correlated) with Contemporary Amperex. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Contemporary Amperex has no effect on the direction of Liaoning Chengda i.e., Liaoning Chengda and Contemporary Amperex go up and down completely randomly.

Pair Corralation between Liaoning Chengda and Contemporary Amperex

Assuming the 90 days trading horizon Liaoning Chengda is expected to generate 2.52 times less return on investment than Contemporary Amperex. But when comparing it to its historical volatility, Liaoning Chengda Biotechnology is 1.51 times less risky than Contemporary Amperex. It trades about 0.1 of its potential returns per unit of risk. Contemporary Amperex Technology is currently generating about 0.17 of returns per unit of risk over similar time horizon. If you would invest  18,282  in Contemporary Amperex Technology on August 28, 2024 and sell it today you would earn a total of  8,128  from holding Contemporary Amperex Technology or generate 44.46% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Strong
Accuracy100.0%
ValuesDaily Returns

Liaoning Chengda Biotechnology  vs.  Contemporary Amperex Technolog

 Performance 
       Timeline  
Liaoning Chengda Bio 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Liaoning Chengda Biotechnology are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Liaoning Chengda sustained solid returns over the last few months and may actually be approaching a breakup point.
Contemporary Amperex 

Risk-Adjusted Performance

13 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Contemporary Amperex Technology are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Contemporary Amperex sustained solid returns over the last few months and may actually be approaching a breakup point.

Liaoning Chengda and Contemporary Amperex Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Liaoning Chengda and Contemporary Amperex

The main advantage of trading using opposite Liaoning Chengda and Contemporary Amperex positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Liaoning Chengda position performs unexpectedly, Contemporary Amperex can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Contemporary Amperex will offset losses from the drop in Contemporary Amperex's long position.
The idea behind Liaoning Chengda Biotechnology and Contemporary Amperex Technology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Other Complementary Tools

Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Bonds Directory
Find actively traded corporate debentures issued by US companies